NCT06049095

A Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally in Healthy Participants

A Sequential, Randomized, Double-Blind, Placebo-Controlled, Phase 1 Single and Multiple Ascending Dose Study of LTG-001 Administered Orally of Intravenously to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Male and Female Participants 18 to 55 Years of Age

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 204 (estimated)
• Sponsor: Latigo Biotherapeutics · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a sequential, randomized, double-blind, placebo-controlled Phase 1 single (SAD) and multiple (MAD) ascending dose study to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally or intravenously administered LTG-001 in healthy male and female participants

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	LTG-001	Oral doses
DRUG	Placebo	Oral doses

Timeline

• Start date: 2023-10-17
• Primary completion: 2026-04-28
• Completion: 2026-04-28
• First posted: 2023-09-21
• Last updated: 2026-01-23

Locations

1 site across 1 country: New Zealand